RICHMOND, Va., March 22 /PRNewswire-FirstCall/ -- Insmed Inc. , a biopharmaceutical company, today announced that Nicholas A. LaBella Jr., MS, RPh, has joined Insmed, effective immediately, as Chief Scientific Officer, a newly-created position on the executive team. Mr. LaBella's primary responsibility will be to oversee the scientific and regulatory analysis related to the Company's ongoing strategic review. He will report directly to Dr. Melvin Sharoky, Insmed's Chairman.
In addition, Mr. LaBella has held a number of senior-level positions within drug development and regulatory affairs at several other leading pharmaceutical companies, including Watson Laboratories, Inc. and the former Sandoz Research Institute.
"I am pleased to be joining the Insmed management team and look forward to significantly contributing to the strategic review," said Mr. LaBella.
About Insmed
Insmed Inc. is a biopharmaceutical company with unique protein development experience and a proprietary protein platform principally aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.
CONTACT: Investor Relations, Brian Ritchie, +1-212-850-5683,
brian.ritchie@fd.com, or Media Relations, Irma Gomez-Dib, +1-212-850-5761,
irma.gomez-dib@fd.com, both of FD for Insmed
Web site: http://www.insmed.com/
